<html><head></head><body><h1>Oxymetazoline</h1><p class="drug-subtitle"><b>Class:</b> Vasoconstrictors<br/>
<b>VA Class:</b> NT100<br/>
<b>CAS Number:</b> 2315-02-8<br/>
<b>Brands:</b> Afrin No Drip Extra Moisturizing, Afrin No Drip Original, Afrin No Drip Severe Congestion, Afrin No Drip Sinus, Afrin Original, Afrin Severe Congestion, Afrin Sinus, Dristan 12 Hour, Neo-Synephrine 12 Hour Severe Sinus Congestion, Nostrilla 12 Hour Nasal Decongestant, Vicks Sinex 12 Hour Nasal Decongestant, Visine L.R. Eye Drops, Zicam Extreme Congestion Relief, Zicam Intense Sinus Relief</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h2>Introduction</h2><p>Vasoconstrictor;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; an imidazoline-derivative sympathomimetic amine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="uses">Uses for Oxymetazoline</h2><h3>Nasal Congestion</h3><p><i>Self-medication</i> for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>As effective as other topical vasoconstrictors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Labeled and has been used for <i>self-medication</i> for temporary relief of nasal congestion associated with sinusitis;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; however, efficacy data are lacking and/or controversial.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;108&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;109&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In October 2005, FDA issued final rule to remove this indication from labeling of OTC nasal decongestants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Compliance date for preparations with annual sales &lt;$25,000 is October 11, 2007; compliance date for all other preparations is April 11, 2007.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;107&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Conjunctival Congestion</h3><p><i>Self-medication</i> for temporary relief of ocular redness due to minor irritation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Otitic Barotrauma</h3><p>Has been used for <i>self-medication</i> for symptomatic prevention of otitic barotrauma† (aerotitis [barotitis] media);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;103&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; however, no more effective than placebo.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Oxymetazoline Dosage and Administration</h2><h3>Administration</h3><p>Administer topically to nasal mucosa or conjunctiva.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer nasal solution intranasally as sprays or nasal pumps.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Prior to initial use of metered sprays, prime nasal inhaler by depressing the pump firmly several times.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer nasal spray or pump into each nostril while head is erect.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer ophthalmic solution topically to the conjunctiva.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Avoid contamination of the dropper tip.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Remove contact lenses before administering ophthalmic solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not administer discolored or cloudy solutions.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>Available as oxymetazoline hydrochloride; dosage expressed in terms of the salt.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-medication</i> in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-medication</i> in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-medication</i>: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For <i>self-medication</i>: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p><i>Self-medication</i> in children ≥6 years of age: Maximum of 2 times (2 doses) in a 24-hour period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p><i>Self-medication</i>: Maximum of 2 times (2 doses) in a 24-hour period.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Oxymetazoline</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to oxymetazoline or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Known sensitivity to the pharmacologic effects of adrenergic drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to oxymetazoline or any ingredient in the formulation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Known sensitivity to the pharmacologic effects of adrenergic drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Possible irritation of nasal mucosa and adverse systemic effects (particularly in children) with excessive dosage and/or prolonged or too frequent intranasal use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Possible rebound nasal congestion or ocular hyperemia (redness);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; avoid prolonged use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><p>Accidental ingestion of imidazoline derivatives (i.e., oxymetazoline, naphazoline, tetrahydrozoline) in children has resulted in serious adverse events requiring hospitalization (e.g., coma, bradycardia, decreased respiration, sedation, somnolence).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1002&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1003&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1004&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1005&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1006&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1007&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pediatric Use under Cautions and also see Advice to Patients.)</p><p>With intranasal use, possible headache, hypertension, cardiac irregularities (e.g., palpitation, reflex bradycardia), nervousness, nausea, dizziness, and insomnia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution and under direction of a clinician in patients with thyroid disease (e.g., hyperthyroidism), heart disease (including angina), hypertension, advanced arteriosclerotic conditions, or diabetes mellitus; in patients experiencing difficulty in urination secondary to prostatic enlargement; or in patients receiving monoamine oxidase (MAO) inhibitors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Patients with narrow-angle glaucoma should consult a clinician before using ophthalmic solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether oxymetazoline is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Use with caution in nursing women.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;113&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>0.05% nasal solution or 0.025% ophthalmic solution not recommended for <i>self-medication</i> in children &lt;6 years of age.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible irritation of nasal mucosa and adverse systemic effects (including profound CNS depression) associated with excessive dosage, prolonged or too frequent use, or inadvertent ingestion of nasal solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Accidental ingestion of OTC ophthalmic solutions or nasal sprays containing imidazoline derivatives (i.e., oxymetazoline, naphazoline, tetrahydrozoline) in children has resulted in serious adverse events requiring hospitalization, including nausea, vomiting, lethargy, tachycardia, decreased respiration, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling, and coma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Keep out of reach of children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Advice to Patients.)</p><h3>Common Adverse Effects</h3><p>Nasal solution: transient burning, stinging, sneezing, increased nasal discharge or dryness of nasal mucosa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Oxymetazoline Pharmacokinetics</h2><h3>Absorption</h3><p>Occasionally, absorption may be sufficient to produce systemic effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following intranasal administration, local vasoconstriction usually occurs within 5–10 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following ocular administration, local vasoconstriction usually occurs within minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following intranasal administration, local vasoconstriction persists for 5–6 hours, with gradual decline over the next 6 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following ophthalmic administration, local vasoconstriction persists for up to 6 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>Room temperature (&lt;40°C); avoid freezing.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>15–30°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; do not store in aluminum containers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Actions</h2><ul>
<li>
<p>Structurally and pharmacologically related to naphazoline, tetrahydrozoline, and xylometazoline.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Directly stimulates α-adrenergic receptors; exerts little or no effect on β-adrenergic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Constricts dilated arterioles, reduces nasal blood flow and congestion, and opens obstructed eustachian ostia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Temporarily relieves nasal and conjunctival congestion following topical application.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Structurally and pharmacologically related to naphazoline, tetrahydrozoline, and xylometazoline.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Directly stimulates α-adrenergic receptors; exerts little or no effect on β-adrenergic receptors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Constricts dilated arterioles, reduces nasal blood flow and congestion, and opens obstructed eustachian ostia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Temporarily relieves nasal and conjunctival congestion following topical application.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>With intranasal use, importance of discontinuing drug and consulting a clinician if nasal congestion worsens or persists for &gt;3 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>With ophthalmic use, importance of discontinuing drug and consulting a clinician if ocular pain or visual changes occur or if ocular redness or irritation worsens or persists for &gt;72 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Overuse of nasal solution may cause recurrence or exacerbation of nasal congestion;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; overuse of ophthalmic solution may produce increased redness of the eye.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of removing contact lenses prior to administration of ophthalmic solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of avoiding contamination of the dropper, inhaler, or spray dispenser.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not touch dropper tip to any surface;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rinse inhaler/spray dispenser tip with hot water or wipe clean following use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; To minimize risk of spreading infections, do not share dropper, inhaler, or spray dispenser with other individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of calling clinician or poison control center if ingested.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of seeking emergency help immediately.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information. (See Cautions.)</p>
</li>
</ul><p>With intranasal use, importance of discontinuing drug and consulting a clinician if nasal congestion worsens or persists for &gt;3 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With ophthalmic use, importance of discontinuing drug and consulting a clinician if ocular pain or visual changes occur or if ocular redness or irritation worsens or persists for &gt;72 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Overuse of nasal solution may cause recurrence or exacerbation of nasal congestion;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; overuse of ophthalmic solution may produce increased redness of the eye.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of removing contact lenses prior to administration of ophthalmic solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of avoiding contamination of the dropper, inhaler, or spray dispenser.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not touch dropper tip to any surface;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;112&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; rinse inhaler/spray dispenser tip with hot water or wipe clean following use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; To minimize risk of spreading infections, do not share dropper, inhaler, or spray dispenser with other individuals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;111&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of calling clinician or poison control center if ingested.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of seeking emergency help immediately.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;1001&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;a&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information. (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name</p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Nasal</p><p>Solution</p><p>0.05%*</p><p>Afrin<sup></sup> No Drip Extra Moisturizing 12 Hour Pump Mist</p><p>Schering-Plough</p><p>Afrin<sup></sup> No Drip Original 12 Hour Pump Mist</p><p>Schering-Plough</p><p>Afrin<sup></sup> No Drip Severe Congestion 12 Hour Pump Mist</p><p>Schering-Plough</p><p>Afrin<sup></sup> No Drip Sinus 12 Hour Pump Mist</p><p>Schering-Plough</p><p>Afrin<sup></sup> Original 12 Hour Spray</p><p>Schering-Plough</p><p>Afrin<sup></sup> Severe Congestion 12 Hour Spray</p><p>Schering-Plough</p><p>Afrin<sup></sup> Sinus 12 Hour Spray</p><p>Schering-Plough</p><p>Dristan<sup></sup> 12 Hour Nasal Spray</p><p>Pfizer</p><p>Neo-Synephrine<sup></sup> 12 Hour Severe Sinus Congestion Spray</p><p>Bayer</p><p>Nostrilla<sup></sup> 12 Hour Nasal Decongestant Metered Pump Spray</p><p>Insight</p><p>Oxymetazoline Hydrochloride Nasal Solution</p><p>Vicks Sinex<sup></sup> 12 Hour Nasal Decongestant Spray (with regular or metered pump mist spray)</p><p>Procter &amp; Gamble</p><p>Zicam<sup></sup> Extreme Congestion Relief Nasal Gel</p><p>Matrixx</p><p>Zicam<sup></sup> Intense Sinus Relief Nasal Gel</p><p>Matrixx</p><p>Ophthalmic</p><p>Solution</p><p>0.025%</p><p>Visine L.R.<sup></sup> Eye Drops</p><p>Pfizer</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions February 20, 2014. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>100. Csortan E, Jones J, Haan M et al. Efficacy of pseudoephedrine for the prevention of barotrauma during air travel. <i>Ann Emerg Med</i>. 1994; 23:1324-7. http://www.ncbi.nlm.nih.gov/pubmed/8198308?dopt=AbstractPlus</p><p>101. Jones JS, Sheffield W, White LJ et al. A double-blind comparison between oral pseudoephedrine and topical oxymetazoline in the prevention of barotrauma during air travel. <i>Am J Emerg Med</i>. 1998; 16:262-4. http://www.ncbi.nlm.nih.gov/pubmed/9596428?dopt=AbstractPlus</p><p>102. Brown M, Jones K, Krohmer J. Pseudoephedrine for the prevention of barotitis media: a controlled clinical trial in underwater divers. <i>Ann Emerg Med</i>. 1992; 21:849-52. http://www.ncbi.nlm.nih.gov/pubmed/1610044?dopt=AbstractPlus</p><p>103. Capes JP and Tomaszewski C. Prophylaxis against middle ear barotrauma in US in hyperbaric oxygen therapy centers. <i>Am J Emerg Med</i>. 1996; 14:645-8. http://www.ncbi.nlm.nih.gov/pubmed/8906761?dopt=AbstractPlus</p><p>104. Newton HB. Neurologic complications of scuba diving. <i>Am Fam Physician</i>. 2001; 63:2211-8. http://www.ncbi.nlm.nih.gov/pubmed/11417773?dopt=AbstractPlus</p><p>105. Carlson S, Jones J, Brown M et al. Prevention of hyperbaric-associated middle ear barotrauma. <i>Ann Emerg Med</i>. 1992; 21:1468-71. http://www.ncbi.nlm.nih.gov/pubmed/1443845?dopt=AbstractPlus</p><p>106. Bettes TN and McKenas DK. Medical advice for commercial air travelers. <i>Am Fam Physician</i>. 1999; 60:801-10. http://www.ncbi.nlm.nih.gov/pubmed/10498108?dopt=AbstractPlus</p><p>107. Food and Drug Administration. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; amendment of final monograph for over-the-counter nasal decongestant drug products. 21 CFR Parts 310 and 341. Final rule. [Docket No. 2004N- 0289] <i>Fed Regist</i>. 2005; 70:58974-7.</p><p>108. Spector SL, Bernstein IL, Li JT et al for the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Parameters for the diagnosis and management of sinusitis. <i>J Allergy Clin Immunol</i>. 1998; 102(Suppl):S107-44. http://www.ncbi.nlm.nih.gov/pubmed/9847450?dopt=AbstractPlus</p><p>109. American Academy of Pediatrics: subcommittee on management of sinusitis and committee on quality improvement. Clinical practice guideline: Management of sinusitis. <i>Pediatrics</i>. 2001; 108:798-808. http://www.ncbi.nlm.nih.gov/pubmed/11533355?dopt=AbstractPlus</p><p>110. Benninger MS, Anon J, Mabry RL. The medical management of rhinosinusitis. <i>Otolaryngol Head Neck Surg</i>. 1997; 117(Suppl):S41-9. http://www.ncbi.nlm.nih.gov/pubmed/9334787?dopt=AbstractPlus</p><p>111. Neo-Synephrine 12 Hour<sup></sup> (oxymetazoline hydrochloride) 0.05% nasal solution prescribing information. In PDR.net [database online]. Montvale, NJ: Thomson Healthcare; 2003. Updated 2003 Oct.</p><p>112. Visine L.R. Long Lasting<sup></sup> (oxymetazoline hydrochloride) 0.025% ophthalmic solution prescribing information. In PDR.net [database online]. Montvale, NJ: Thomson Healthcare; 2003. Updated 2003 Oct.</p><p>113. Wickersham, RM. Drug Facts and Comparisons. 2003. St Louis, MO: Facts and Comparisons; 2003: page 685.</p><p>114. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2005:1227-8.</p><p>1001. US Food and Drug Administration. FDA drug safety communication: Serious adverse events from accidental ingestion by children of over-the-counter eye drops and nasal sprays. Rockville, MD; 2012 Oct 25. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm</p><p>1002. Tobias JD. Central nervous system depression following accidental ingestion of Visine eye drops. <i>Clin Pediatr (Phila)</i>. 1996; 35:539-40. http://www.ncbi.nlm.nih.gov/pubmed/8902333?dopt=AbstractPlus</p><p>1003. Katar S, Taskesen M, Okur N. Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication. <i>Pediatr Int</i>. 2010; 52:488-9. http://www.ncbi.nlm.nih.gov/pubmed/20723124?dopt=AbstractPlus</p><p>1004. Holmes JF, Berman DA. Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child. <i>Pediatr Emerg Care</i>. 1999; 15:193-4. http://www.ncbi.nlm.nih.gov/pubmed/10389957?dopt=AbstractPlus</p><p>1005. Vitezic D, Rozmanic V, Franulovic J et al. Naphazoline nasal drops intoxication in children. <i>Arh Hig Rada Toksikol</i>. 1994; 45:25-9. http://www.ncbi.nlm.nih.gov/pubmed/8067910?dopt=AbstractPlus</p><p>1006. Mahieu LM, Rooman RP, Goossens E. Imidazoline intoxication in children. <i>Eur J Pediatr</i>. 1993; 152:944-6. http://www.ncbi.nlm.nih.gov/pubmed/8276031?dopt=AbstractPlus</p><p>1007. Higgins GL, Campbell B, Wallace K et al. Pediatric poisoning from over-the-counter imidazoline-containing products. <i>Ann Emerg Med</i>. 1991; 20:655-8. http://www.ncbi.nlm.nih.gov/pubmed/2039105?dopt=AbstractPlus</p><p>a. AHFS Drug Information 2014. McEvoy GK, ed. Oxymetazoline Hydrochloride. Bethesda, MD: American Society of Health System Pharmacists.</p><h2>More about oxymetazoline ophthalmic</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>Breastfeeding</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: ophthalmic antihistamines and decongestants</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Oxymetazoline Ophthalmic &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Blepharoptosis</li>
<li>Eye Redness</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>